EAGLE is an MRC funded international multi-centre pragmatic randomised controlled trial (RCT) aiming to establish whether removal of the lens of the eye (lens extraction) for newly diagnosed Primary Angle Closure Glaucoma (PACG) results in better patient reported health, vision, lower intraocular pressure (IOP) and other outcomes compared with standard management.

22 specialist centres in the UK and nine International centres (two in Singapore, two in Hong Kong, two in Malaysia and one in Australia) are participating.

Research coordinators in each centre have recruited 419 people newly diagnosed with PACG who have met the eligibility criteria. EAGLE patient follow-up will consist of several visits to the hospital for data collection (physical clinical measures and questionnaires) at 6, 12, 24 and 36 month post randomisation. Regular clinic follow-up will also continue as clinically indicated between study outcome visits.





EAGLE Lancet Publication

Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial